An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer
- PMID: 7819055
- PMCID: PMC2033467
- DOI: 10.1038/bjc.1995.17
An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer
Abstract
Meta-analysis of the published results from 54 randomised controlled trials of adjuvant chemotherapy in head and neck cancer suggests that chemotherapy might increase absolute survival by 6.5% (95% confidence interval 3.1-9.9%). The odds ratio in favour of chemotherapy is 1.37 (95% confidence interval 1.24-1.5). Single-agent chemotherapy given synchronously with radiotherapy increased survival by 12.1% (95% confidence interval 5-19%). The benefit from neoadjuvant chemotherapy was less: a rate difference of 3.7% (95% confidence interval 0.9-6.5%). The results suggest that the investigation of optimal agents and scheduling for synchronous radiotherapy and chemotherapy might still be important in clinical trials in head and neck cancer.
Comment in
-
Meta-analysis of chemotherapy in head and neck cancer: individual patient data vs literature data.Br J Cancer. 1995 Oct;72(4):1062-3. doi: 10.1038/bjc.1995.462. Br J Cancer. 1995. PMID: 7547223 Free PMC article. No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
